Superdisintegrant Composite Particles for Drug Nanoparticle Recovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The integration of nanoparticles into solid dosage forms often results in aggregation and loss of surface area during drying, leading to poor drug recovery and bioavailability, especially for poorly water-soluble drugs, and existing methods rely heavily on surfactants that can cause instability and irritation in inhalation applications.
Innovation Solution
The use of surfactant-free or near surfactant-free formulations incorporating wet-milled superdisintegrant-based composite particles to break up nanoparticle aggregates and enhance recovery and dissolution of active pharmaceutical agents, achieved through wet milling and co-grinding with stabilizers like HPMC and HPC, and embedding these particles in core-shell or matrix formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If nanoparticles are integrated into solid dosage forms through drying of nano-suspensions, then solid dosage forms can be produced, but nanoparticles aggregate and lose surface area during drying
Solution Approach 1:
The patent introduces superdisintegrants as intermediary substances that mediate between the nanoparticles and the drying process. These superdisintegrants form a protective matrix around nanoparticles during drying, preventing direct nanoparticle-nanoparticle contact that would cause aggregation. The superdisintegrant acts as a spacer and protective barrier, allowing solid dosage form production while preserving nanoparticle surface area.
Solution Approach 2:
The patent creates composite particles consisting of nanoparticles embedded within a superdisintegrant matrix. This composite structure combines the therapeutic function of nanoparticles with the protective and disintegrating properties of superdisintegrants. The composite particle architecture allows the solid dosage form to maintain nanoparticle surface area while enabling manufacturing processes.
2Reliability
If surfactants are used to prevent nanoparticle aggregation during drying, then nanoparticle stability is improved, but physical instability occurs through Ostwald ripening and agglomeration
Solution Approach 1:
The patent extracts and eliminates surfactants from the formulation system, replacing them with superdisintegrants. By removing the harmful surfactant component while retaining the protective function through alternative mechanisms (superdisintegrant matrix), the patent resolves the contradiction between nanoparticle stability and physical stability of suspensions.
Solution Approach 2:
The patent changes the chemical and physical parameters of the dispersing agent from surfactant-based to superdisintegrant-based systems. This parameter change fundamentally alters the mechanism of nanoparticle stabilization, shifting from surfactant-mediated steric/electrostatic stabilization to superdisintegrant-mediated matrix protection, thereby eliminating Ostwald ripening and agglomeration issues.
3Productivity
If dispersants are added to enhance drug nanoparticle recovery from dried particles, then re-dispersion speed is improved, but formulation complexity increases
Solution Approach 1:
The patent makes the superdisintegrant perform multiple functions simultaneously: (1) acting as a dispersing agent during manufacturing, (2) forming a protective matrix during drying, (3) enabling rapid re-dispersion of nanoparticles, and (4) providing disintegration function in the final dosage form. This multi-functionality eliminates the need for separate dispersants, reducing formulation complexity while maintaining high nanoparticle recovery rates.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for faster and more effective recovery and dissolution of drug nanoparticles, reducing the need for surfactants and minimizing physical instability, thereby improving bioavailability and stability of poorly water-soluble drugs in solid dosage forms.
Implementation Method 1
wet-milled superdisintegrant (SDI) particles...can also be used to break-up the aggregates (e.g., nanoparticle aggregates) of the active agents
Implementation Method 2
The advantageous SDI particles (e.g., colloidal/ultrafine SDI particles)...provide for the release and efficient recovery and/or dissolution of drug nanoparticles
Implementation Method 3
co-wet-milling the SDI particles and the active agent particles to form a mixture of wet-milled SDI particles and active agent particles
Implementation Method 4
converting bigger particles into nanoparticles significantly enhances diffusion properties as a result of the large surface area which nanoparticles provide
Implementation Method 5
The nano-suspensions containing active agents can be dried (e.g., by spray drying, spray freeze drying, freeze drying, etc.)
Implementation Method 6
During the drying processes, nanoparticles tend to aggregate and form larger particles
Implementation Method 7
co-wet-milling the SDI particles and the active agent particles in a wet media mill in the presence of stabilizers
Implementation Method 8
incorporating a wet milled superdisintegrant (SDI) as a dispersant in the formulation
Data Source
AI summary
The present disclosure provides improved systems and methods utilizing colloidal/ultrafine superdisintegrant-based composite particles for dispersion and/or dissolution of active pharmaceutical agents. In general, the present disclosure utilizes a surfactant-free or near surfactant-free formulation by incorporating a wet milled SDI as a dispersant in the formulation. As such, the present disclosure provides for the preparation of surfactant-free or substantially surfactant-free formulations (e.g., nano-composite micro-particle formulations) by incorporating a wet-milled superdisintegrant (SDI) as the dispersant in the formulations. The advantageous SDI particles (e.g., colloidal/ultrafine SDI particles) of the present disclosure can be used to break-up the aggregates (e.g., nanoparticle aggregates) of the active agents (e.g. poorly water-soluble drugs) in the formulations (e.g., micro-particle formulations) and enhance the recovery of the nanoparticles of active agents during aqueous re-dispersion and their dissolution rate in vitro and in vivo.